Login to Your Account


Spinal gap: Neuralstem goes into chronic injuries phase I, first ever cleared by FDA

By Randy Osborne
Staff Writer

Thursday, October 9, 2014
With encouraging data from a phase I trial in amyotrophic lateral sclerosis (ALS) and a phase II trial under way testing NSI-566, Neuralstem Inc. has begun – with the same candidate – the first human neural stem cell study to be given the FDA's nod for chronic spinal cord injury.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription